NCT01243307 - A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2011

Study Completion Date

May 31, 2011

Conditions

Neuropathic Pain

Interventions

DRUG

CT327 (or placebo) followed by placebo (or CT327)

"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."

Trial Locations (1)

9000

Department of Gastroenterology Aalborg Hospital, Aalborg